Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29951442 | 1.00 | DGAT1 (0.56) | DGAT1PARP10PARP15CES2CES1 | |
| SCHEMBL790041 | 0.85 | DGAT1 (0.43) | DGAT1CES2CES1MAP2K2MAP2K1 | |
| SCHEMBL29689051 | 0.82 | CES2 (0.41) | CES2CES1MAP2K2MAP2K1TTR | |
| SCHEMBL362047 | 0.82 | CES2 (0.41) | CES2CES1MAP2K2MAP2K1TTR | |
| SCHEMBL3786848 | 0.82 | ENPP2 (0.39) | DGAT1TTRALDH1A1CA1CA2 | |
| SCHEMBL1319282 | 0.81 | MAOB (0.43) | DGAT1CES2CES1ALDH1A1CA1 | |
| SCHEMBL30963904 | 0.81 | MAOB (0.43) | DGAT1CES2CES1ALDH1A1CA1 | |
| SCHEMBL13644473 | 0.81 | ALDH1A1 (0.48) | DGAT1CES2CES1TTRALDH1A1 | |
| SCHEMBL16096308 | 0.80 | ALDH1A1 (0.43) | DGAT1CES2CES1ALDH1A1CA1 | |
| SCHEMBL15375492 | 0.78 | ALDH1A1 (0.41) | DGAT1TTRALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-09-19 | — | — | US | disclosed |
| WO-2024173323-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2010128324-A1 | SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750 | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | DGAT1 2190/4885PARP10 196/4885PARP15 30/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | DGAT1 4872/4885PARP10 3343/4885PARP15 4023/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | DGAT1 1085/4885PARP10 4728/4885PARP15 4736/4885 |
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | DGAT1 874/4885PARP10 3610/4885PARP15 3609/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | DGAT1 3451/4885PARP10 677/4885PARP15 938/4885 |
| US-12030889-B2 | Imidazopyridazine and imidazopyridine compounds and uses thereof | ALK, ABL2, ACVR2A | DGAT1 4345/4885PARP10 2867/4885PARP15 737/4885 |
| US-20100261701-A1 | 8-Substituted isoquinoline derivative and the use thereof | RELA, NFKBIA, NFKB2 | DGAT1 2713/4885PARP10 1656/4885PARP15 1217/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | DGAT1 816/4885PARP10 3463/4885PARP15 3471/4885 |
| US-20240309008-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | ALK, ABL2, ACVR2A | DGAT1 4345/4885PARP10 2867/4885PARP15 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.